CHICAGO & DUBLIN, Calif. & JENA, Germany--(BUSINESS WIRE)--Nov 10, 2012--Medical technology provider Carl Zeiss Meditec announced today the introduction of a new family of ZEISS OCT (Optical Coherence Tomography) products at the 2012 AAO-APAO Joint Meeting in Chicago. The new CIRRUS OCT family is comprised of two new CIRRUS™ HD-OCT products, models 5000 and 500, and two new integrated multi-modality OCT and fundus imaging systems, the CIRRUS™ photo models 800 and 600. The new OCT platforms deliver clinical and workflow solutions that span the spectrum of care and address specific workflow and practice needs.
“The new CIRRUS family offers a choice of high-quality ZEISS OCT clinical solutions for the diagnosis and management of glaucoma and retinal disease across all levels of care, from comprehensive practices to advanced subspecialty practices,” says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. “Practitioners can now benefit from diagnostic and workflow solutions that are tailored specifically for the level of care they provide, their practice workflow and their case load volumes. The new family of OCT products enables more practitioners to offer patients a high level of care and to tailor their investment to their workflow and practice needs.” The CIRRUS HD-OCT 5000 has been optimized for advanced care with new FastTrac™ retinal tracking that enables the highest resolution B-Scans to be captured in identical locations from visit to visit providing accurate assessment of change in targeted pathologies. FastTrac compensates for eye motion during scanning and can be optionally turned on to assist with poor fixators to optimize patient throughput.
“With CIRRUS FastTrac, I can place a highest resolution 20x B-Scan precisely on the area I am treating at each successive visit to see the fine details of the patient’s response to treatment,” says SriniVas Sadda MD, Director of the Medical Retina Service at Doheny Eye Institute in Los Angeles, California. “It’s also very helpful for removing any eye motion from the larger cube scans without disturbing my patient flow because it works so quickly. My initial experience is that FastTrac is about 30 percent faster than other tracking methods I have used.” Additionally, to meet the needs of advanced care, the CIRRUS HD-OCT 5000 is configured with the highest resolution visualization capabilities and sophisticated applications, such as Advanced RPE Analysis to track retinal pigment epithelial integrity, and Ganglion Cell Analysis to assess glaucomatous loss in the macula that may not be evident in the peripapillary region.
Both the CIRRUS HD-OCT 5000 and 500 feature a new modernized OCT platform with faster processing and OCT camera systems. The new contemporary designs with larger viewing monitors and wireless keyboard and mouse fit into today’s modern practice environments. Both models come equipped with ZEISS‘ comprehensive suites of clinical applications for retina and glaucoma and with time-based historical data and normative data comparison analysis tools to support efficient and confident patient management.
The CIRRUS HD-OCT 500 has been designed for comprehensive ophthalmic practices which require essential OCT capabilities and reliability in an easy-to-learn, easy-to-use instrument. The new faster OCT camera enables quick OCT fundus image refresh making patient alignment more efficient.
The CIRRUS photo 800 and 600 multi-modality systems combine standard-setting CIRRUS OCT technology with full-featured mydriatic/non-mydriatic fundus imaging in one integrated compact and versatile system. Practitioners can correlate data from high-density OCT cubes, thickness and layer maps with results from superb color fundus, and angiography images in one imaging session without the need to move the patient.
“CIRRUS photo gives the opportunity to make complete fundus images without asking the patient to move from one machine to another,” says Professor Jean-François Korobelnik, MD. “OCT and color and autofluorescence are very useful together for the diagnosis and the follow up of macular diseases.” The CIRRUS photo 800 is designed to support advanced disease management with fluorescein and ICG angiography, color and fundus autofluorescence imaging, and OCT technology in an integrated imaging solution. The CIRRUS photo 600 combines non-mydriatic color imaging and OCT with a fundus autofluorescence option and is designed for comprehensive eye care practices needing efficient fundus imaging and essential OCT capabilities for assessment and management of a broad range of conditions.
The CIRRUS HD-OCT 5000 and 500 are immediately available for sale in the US and other markets. The CIRRUS photo 800 and 600 are to be released globally in early 2013.
The new CIRRUS OCT family will be on display in ZEISS booth #534 during the 2012 AAO-APAO Joint Meeting in Chicago November 10 to 13, 2012.
Brief profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on TecDax of the German stock exchange, is one of the world’s leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumables. The company creates innovative visualization solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In fiscal year 2010/11 (ended 30 September) the company's around 2,400 employees generated revenue of EUR 759 million.
The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Research and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the presence in these rapidly developing economies. 35 percent of Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries. Carl Zeiss offers innovative solutions for the future-oriented markets of Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.
For more information, please go to: www.meditec.zeiss.comCONTACT: Contact for the press: Jann Gerrit Ohlendorf, Director Corporate Communications, Carl Zeiss Meditec AG +49 36 41 220-331 firstname.lastname@example.org or Contact for investors: Henriette Meyer, Director Investor Relations, Carl Zeiss Meditec www.meditec.zeiss.com/press KEYWORD: UNITED STATES EUROPE NORTH AMERICA CALIFORNIA ILLINOIS GERMANY INDUSTRY KEYWORD: SURGERY TECHNOLOGY SOFTWARE OTHER TECHNOLOGY HEALTH MEDICAL DEVICES OPTICAL SOURCE: Carl Zeiss Meditec AG Copyright Business Wire 2012 PUB: 11/10/2012 04:53 PM/DISC: 11/10/2012 04:53 PM http://www.businesswire.com/news/home/20121110005061/